AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03624543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: 32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
Study NCT01958216 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous injection of deuterated cholesterol diluted in intralipid 20%
Description: At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
Study NCT02361060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 40mcg/kg
Study NCT02361060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 4mg/kg
Study NCT02361060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 10 mcg/kg
Study NCT03684720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discover followed by direct instruction [DD]
Description: The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
Study NCT03096301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity laser
Description: Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
Study NCT03096301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal plates
Description: The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment
Study NCT03096301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
Study NCT03096301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
Study NCT03096301 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
Study NCT03847623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Natural compound, active ingredient of turmeric, in bi-daily dosing
Study NCT03847623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets at bi-daily dosing
Study NCT04230460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis (THC) (Inhaled) Placebo
Description: Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
Study NCT04230460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (High% THC) (Inhaled)
Description: Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
Study NCT04230460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (Very High% THC) (Inhaled)
Description: Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
Study NCT04230460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (oral)
Description: Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
Study NCT04062435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drop application in the inferior fornix
Description: See Arms
Study NCT04062435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drop application on the cornea
Description: See Arms
Study NCT02779023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Insomnia (CBT-I)
Study NCT04665310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor
Study NCT02454036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBI intervention
Description: Psychological intervention designed to reduce stress and enhance quality of life
Study NCT00278590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic stem cell transplantation will be performed.
Study NCT01570595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Tailored Smoking Cessation Intervention
Description: The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
Study NCT01570595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Tailored Smoking Cessation Intervention
Description: The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
Study NCT01570595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
Study NCT01426282 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: no intervention
Study NCT01426282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: 15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults
Study NCT01231243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
Study NCT01231243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in-office bleaching with/without light
Description: Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study NCT00119262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given SC
Study NCT00119262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00119262 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase inhibition therapy
Description: Receive aromatase inhibition therapy
Study NCT00119262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatase inhibition therapy
Description: Receive aromatase inhibition therapy
Study NCT00423852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00423852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00423852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00423852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00423852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study NCT00423852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00363194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib (GW786034)
Study NCT00572624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
Study NCT00572624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Description: The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
Study NCT03692221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC Treatment group 1 (low dose)
Description: Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
Study NCT02402465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be treated by placebo
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram will be done for P300 wave assessment
Study NCT02402465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Patients will receive fluticasone nasal spray
Study NCT02402465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Azelastine nasal spray
Description: Patients will receive Dymista nasal spray
Study NCT02402465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
Study NCT02402465 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Allergen Challenge
Description: All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
Study NCT01599377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg
Description: Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
Study NCT01599377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg
Description: Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
Study NCT02615834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gentle chest pressure
Description: Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
Study NCT02105727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based salt reduction
Study NCT00317603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Lethally Irradiated Breast Cancer Cells
Description: Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029 150 mg
Description: 150 mg tablet administered orally, once a day (QD), at bedtime
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-1029 Matching-image Placebo
Description: Matching-image placebo tablet administered orally, QD, at bedtime
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: 10 mg tablet administered orally, QD, at bedtime
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10 mg
Description: 10 mg tablet administered orally, QD, at bedtime
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
Study NCT02720081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
Study NCT01620398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BALANCE
Study NCT01620398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
Study NCT04632797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hilotherm Chemo Care
Description: Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
Study NCT00586742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: labral repair
Description: labral repair with suture anchors
Study NCT00586742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biceps tenodesis
Description: biceps tenodesis with suture anchor
Study NCT00586742 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: diagnostic arthroscopy
Description: diagnostic arthroscopy
Study NCT03738254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Guardians: A smartphone game
Description: The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey.
Study NCT03738254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Survey
Description: Paper version of daily survey
Study NCT03738254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Survey
Description: Electronic version of daily survey administered via a smartphone app.
Study NCT00439647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg iv
Description: Zoledronic acid 5 mg iv given once a year.
Study NCT00439647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous (i.v.) once a year
Study NCT00825734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
Study NCT00825734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
Study NCT04112875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: Handled powdered supplement to be mixed with water, has orange flavor for oral use.
Study NCT04112875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.